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Aim: The Ewing sarcoma family of tumors (ESFT) is a group of malignant small round cell neoplasms of
bones and soft tissues closely histogenetically related. Methylthioadenosine phosphorylase (MTAP) defi-
ciency has been recently associated with increased tumor aggressiveness and poor outcomes in different
types of neoplasms. However, the expression of this biomarker and its biological role in ESFT remain largely
unknown. Methods: Immunohistochemical expression of MTAP was accessed in 112 patients with ESFT in
a tissue microarray platform and associated with clinicopathological parameters and overall survival (OS).
Results: Loss of MTAP expression was significantly associated with lower OS in both univariate and mul-
tivariate analyses. Conclusion: Loss of MTAP expression is an independent negative prognostic biomarker
in ESFT.
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Methylthioadenosine phosphorylase (MTAP) is a protein product of the tumor suppressor gene located in the
chromosome 9p21 region, close to the p16 gene (CDKN2), which plays an important role in the metabolism of
purines and polyamines [1]. In normal cells, MTAP cleaves MTA, a by-product of polyamine biosynthesis, into
adenine and MTR-1-P. In MTAP-deficient cells, however, the MTA is not cleaved and the salvage pathway for
adenine and methionine is absent, causing a stimulus for the de novo synthesis of purines [2].
Deficiency of this enzyme has been recently found in different types of neoplasms, mainly due to deletion of the
9p21 locus, and associated with increased tumor aggressiveness [1,3–5]. Su et al. (2014), in an immunohistochemistry
(IHC) study of 99 lung cancer samples, demonstrated that MTAP was an independent marker of prognosis in
patients with non-small-cell lung cancer [3]. In the study by Becker et al. (2015), the authors suggested that
loss of MTAP expression may also be associated with increased malignancy of brain gliomas [5]. Similarly, De
Oliveira et al. (2016), in a recent breast cancer study, found that loss of MTAP expression was associated with
more aggressive tumor subtypes [4]. One of the possible explanations for the association with tumor aggressiveness
is that in neoplastic cells MTAP inactivation stimulates de novo synthesis of purines, which is related to increased
cell proliferation [5]. In contrast, MTAP-deficient neoplastic cells are more sensitive to purine synthesis inhibitor
agents, such as methotrexate, azathioprine and 5′-fluorouracil (5′-FU), which indicates that MTAP is a promising
therapeutic target [2]. However, to date there are no reports on the IHC expression of MTAP in Ewing sarcoma
family of tumors (ESFT).
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The ESFT comprises a spectrum of malignant neoplasms, consisting of small round cells with varying degrees
of neuroectodermal differentiation, including bone and extraskeletal Ewing sarcoma, the so-called primitive neu-
roectodermal tumor (PNET) and Askin tumor [6]. These tumors are characterized by translocations involving one
of the genes of the TET/FET family and one of the genes of the ETS family, most commonly EWSR1 and FLI1
[t(11, 22) (q24; q12)], generating an aberrant transcription factor that can activate or repress other genes involved
in the oncogenesis [7].
Over the last decades the therapeutic advances have brought a positive impact in reducing mortality of the
disease, however the treatment of patients with localized or disseminated disease is still practically the same. That
is, the differences between individuals and the biological differences between tumors are currently being ignored.
Therefore, it is important to identify the tumors that may require different therapeutic interventions, especially
those that can be more aggressive, with a greater chance of early metastasis and frequent relapses. The broader
knowledge of the biology of ESFT and the interaction with each patient may contribute to the emergence of new
personalized therapeutic modalities, especially molecular targeted therapies and, in this context, IHC also plays
a relevant role. The immunohistochemical method is a widely and routinely used technique in most pathology
laboratories. Much of the molecular findings of diseases, especially neoplasms, are validated or even originated from
the evaluation of protein expression by IHC.
The aim of the present study was to evaluate the expression of MTAP by IHC and assess its clinicopathological
impact in a well-characterized series of ESFT in a Brazilian population, in order to determine the value of this
biomarker as a prognostic factor.
Materials & methods
Patients & tumor samples
Tumor samples from 112 patients with diagnosis of ESFT were retrieved from the Pathology Department of the
Barretos Cancer Hospital, Brazil. All patients were diagnosed between 2001 and 2015 and the samples were taken
from primary tumor biopsies prior to the use of any possible systemic treatment.
The diagnoses were confirmed by two independent expert pathologists of bone/soft tissue tumors, using all
the methods currently used in routine pathology for diagnosis of ESFT, such as IHC, FISH and PCR. New IHC
reactions, including CD99, Fli1 and NKX2.2 were used to confirm the diagnosis in all the reviewed cases, whereas
FISH or PCR was applied in 67 out of 112 cases due to the paucity of tumor cells in many biopsy samples. The
patients were grouped according to gender, age (<20 and ≥20 years old), ethnicity (white and non-white), tumor
location (axial vs peripheral and bone vs soft tissues) and disease stage at diagnosis (localized and disseminated).
The study was conducted following national and institutional ethical policies and it was previously approved by
the Barretos Cancer Hospital Ethical Committee (protocol 935/2015). Since it was classified as having minimal
risk, ensuring confidentiality and not resulting in any clinical influences for the patients, the ethical committee
waived the need for consent in this study.
Tissue microarray construction
After review of the cases and in case of sufficient tissue availability, the tumor areas of the respective paraffin
blocks were marked for subsequent extraction and construction of tissue microarray (TMA). The TMAs were
assembled using the Tissue Arrayer MTA-1 platform (Beecher Instruments, Inc., WI, USA). To represent possible
heterogeneity of tumors and to avoid material losses due to wear or detachment, two 1.0-mm cores from each case
were used in two TMA blocks. Non-neoplastic tissue was also added in the TMA blocks for use as positive controls.
The TMAs were cut at 4.0 μ in the microtome and their sections were stained with hematoxylin and eosin for
histological re-examination and for subsequent immunohistochemical reactions.
Immunohistochemical analysis
A manual immunohistochemical assay on the TMA slides was performed for subsequent MTAP evaluation as
previous reported [5]. Starfrost R© adhesive slides (Kinttel, Braunshweig, Germany) were used for the immunohisto-
chemical study. The slides were submitted to dewaxing and hydration by means of sequential baths of xylol and
ethyl alcohol. Briefly, following sample dehydration and antigen retrieval for 4 min at 125◦C and 20 min at 90◦C
with a mixed buffer (citrate 10 mM/EDTA 1 mM, pH 6.0) the slides were incubated with the MTAP polyclonal
antibody (Proteintech Group, Inc., cat 11475–1-AP) at a 1:300 dilution at room temperature overnight. The slides
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Table 1. Clinicopathological features of the Ewing sar-
coma family of tumors patients (Barretos Cancer Hospital,
2001–2015).
Variable N (%)
Gender:
– Female 36 (31.9)
– Male 77 (68.1)
Ethnicity:
– White 93 (83.0)
– Non-white 19 (17.0)
Age:
– ≤20 years 74 (65.5)
– 20 years 39 (34.5)
Tumor size:
– Small† 9 (11.5)
– Large 69 (88.5)
Tumor location (tissue):
– Bone 66 (58.4)
– Soft tissues 47 (41.6)
Tumor location (topography):
– Axial 59 (52.2)
– Peripheral 54 (47.8)
Disease extent at diagnosis:
– Localized 54 (49.5)
– Metastatic 55 (50.5)
†≤8 cm in bone or ≤5 cm in soft tissues (based on TNM staging system).
were then incubated with secondary antibody and streptavidin peroxidase, stained with 3,3′ diaminobenzidine
chromogen and finally counterstained with hematoxylin.
The intensity and extension ofMTAP immunoreactivity in the cytoplasm and/or nucleous were scored. Intensity
of immunoreactivity was measured as: 0 (no staining); 1 (weak staining); 2 (moderate staining) and 3 (strong
staining). The extension of immunoreactivity was assessed as: 0 (negative), 1 (≤25% of positive cells), 2 (25–50%
of positive cells); or 3 (≥50% of positive cells). The sum of both parameters resulted in scores that finally classified
the reactions as loss of expression (0–2) or retained expression (3–6).
Statistical analysis
The statistical analysis was performed using SPSS version 21.0 for WindowsTM (IBM, IL, USA). For all variables,
including clinical demographic characteristics and results of immunohistochemical reactions, frequencies and
percentages were calculated. Associations betweenMTAP expression and the patient’s characteristics were performed
using the Pearson χ2 test or Fisher’s exact test, depending on the expected values in the contingency tables. The
overall survival (OS) analysis was done by constructing Kaplan–Meier curves and for a comparison between the
obtained curves, the log-rank test was applied. An additional analysis of OS was done by separating the patients into
two groups: metastatic and nonmetastatic. OS was defined as the time between the date of diagnosis and the date of
the last patient’s information or death for any reason. In order to adjust for multiple prognostic factors, including
the clinical parameters, and estimate the independent effect of MTAP expression on survival, a multivariate analysis
was applied by the Cox regression method.
Results
The clinicopathological features of the ESFT patients & associations with MTAP expression
The clinicopathological features of ESFT cases are summarized in Table 1. One-, 3- and 5-years OS were 69.9, 46
and 30.3%, respectively. The male:female ratio in this study was 2.1:1. The majority of patients were white (83%)
and 20 years old or younger (65.5%). Patient’s age ranged from 2 to 67 years, with a mean of 19 years (standard
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Figure 1 Methylthioadenosine phosphorylase immunohistochemistry expression. Positive cytoplasmic expression
was observed in the majority of cases (A & B) 400×. (C & D) 400× are examples of cases with total loss of MTAP
expression in tumor cells. In (D) positive endothelial cells were also observed and served as internal controls for the
reaction.
deviation: 12) and a median of 17 years (Q1: 12 and Q3: 21). Tumor dimensions ranged from 3.3 to 35.0 cm, with
a mean of 12.2 cm (standard deviation: 5.8) and a median of 11.0 cm (Q1: 8.5 and Q3: 14.5). A large proportion
(50.5%) of patients with metastasis at diagnosis was observed in this series.
Adequate IHC reactions were achieved in 111/112 of the cases. The IHC revealed cytoplasmicMTAP expression
in 80/111 tumors (72.1%; Figure 1A&B). Thirty-one cases (27.9%) presented loss ofMTAP expression (Figure 1C
& D).
We observed that MTAP expression profile was not significantly associated with the clinicopathological charac-
teristics evaluated in the ESFT patients (Table 2).
Association of MTAP expression with ESFT patients’ prognosis
MTAP expression presented a statistically significant association with OS, according to the Kaplan–Meier and
log-rank methods (p = 0.028; Figure 2). Patients with loss of MTAP expression had a 5-year OS rate of only
11.5%, compared with 37.2% of patients with positive MTAP expression (Table 3). When patients were separated
into two groups, metastatic and nonmetastatic, MTAP showed a statistically significant association with OS in the
group of patients with metastasis (p = 0.021). In the metastatic group, patients with loss of MTAP expression had
a 3-year OS rate of only 16.7%, compared with 35.0% of patients with positive MTAP expression. Regarding the
other evaluated clinical characteristics, our results showed that non-white ethnicity (p= 0.002), age over 20 years (p
= 0,023) andmetastatic disease at diagnosis (p= 0,003) significantly influenced the OS (Table 3). The multivariate
analysis, by the COX regression method, revealed that only loss of MTAP expression, ethnicity and metastasis at
diagnosis were independent prognostic factors (Table 4). Regarding the metastatic group and non-metastatic group
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Table 2. Association of MTAP expression with the clinicopathological features.
Characteristic Loss of expression Positive expression p-value†
n % n %
Gender:
– Female 9 29.0 26 32.5 0.724
– Male 22 71.0 54 67.5
Ethnicity:
– White 25 80.6 67 84.8 0.595
– Non-white 6 19.4 12 15.2
Age:
– ≤20 years 20 64.5 52 65.0 0.962
– 20 years 11 35.5 28 35.0
Tumor size:
– Small 1 4.0 7 13.7 0.259
– Large 24 96.0 44 86.3
Tumor location (tissue):
– Bone 18 58.1 47 58.8 0.948
– Soft tissues 13 41.9 33 41.3
Tumor location
(topography):
– Axial 16 51.6 41 51.3 0.973
– Peripheral 15 48.4 39 48.8
Disease extent at
diagnosis:
– Localized 15 48.4 38 50.0 0.880
– Metastatic 16 51.6 38 50.0
†Pearson chi-square test for all variables, except tumor size (Fisher’s test).
of patients, the multivariate analysis also showed a statistically significant association of MTAP loss with poorer OS
in the metastatic group (Table 5).
Discussion
Although ESFT are high-grade sarcomas with a high metastasis rate, a significant increase in survival rates has been
observed in the last few decades with the use of a multimodal therapeutic approach that includes chemotherapy,
surgery and radiotherapy [8,9]. On the other hand, the survival rates for patients with metastatic or recurrent ESFT
did not improve significantly, despite aggressive treatment [8–11].
The characterization of this Brazilian series of ESFT showed that more than half (50.5%) of the patients (n= 54)
had metastatic disease at diagnosis. This frequency is substantially higher than that observed in the literature, which
typically describes the frequency of cases with metastasis at diagnosis around 25% [6,8,9,12]. However, Brunetto et
al. (2015) [10] had already demonstrated a significantly higher proportion of patients with metastatic disease in a
Brazilian population, suggesting that this characteristic could reflect an association of multiple factors related to
access and efficiency of the health system in Brazil. Barretos Cancer Hospital (BCH) is one of the largest cancer
hospitals in Latin America, treating patients from all Brazilian states with 100% free services, covered by the
National Health System of Brazil (SUS), and therefore, a reference bias for receiving more advanced cases must be
considered. Although socioeconomic status was not a variable exploited in this study, the possibility of this factor
influencing the frequency of cases with metastatic disease at diagnosis cannot be ruled out, just as demonstrated by
Lee J et al. (2010) [12]. Many patients treated at BCH are very poor people and have passed through smaller and less
specialized centers in their regions, being admitted after a long delay in diagnosis and initiation of treatment [13].
The extent of the disease at diagnosis is the most consistent prognostic factor according to the literature [8–10,12,14].
The results of the present study were consistent with previous studies, with a significantly lower OS in patients with
metastatic disease, as expected. Multivariate analysis confirmed metastatic disease at diagnosis as an independent
prognostic factor in our series of ESFT (p = 0.002).
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Table 3. Association of MTAP expression and clinicopathological features with overall survival.†
Characteristic Number of cases Number of deaths OS (%) p-value
1 year 3 years 5 years
MTAP:
– Loss of expression 31 24 58.1% 37.3% 11.5% 0.028
– Positive expression 80 46 75.0% 50.7% 37.2%
Gender:
– Female 36 20 75.0% 49.3% 36.1% 0.476
– Male 77 52 67.5% 44.7% 27.7%
Ethnicity:
– White 93 54 74.2% 51.9% 35.7% 0.002
– Non-white 19 17 52.6% 21.1% 7.0%
Age:
– ≤20 years 74 44 75.7% 54.5% 35.8% 0.023
– 20 years 39 28 59.0% 26.9% 17.9%
Tumor Size:
– Small 9 4 88.9% 55.6% 55.6% 0.162
– Large 69 47 65.2% 43.1% 24.1%
Tumor location
(tissue):
– Bone 66 45 74.2% 42.6% 26.5% 0.602
– Soft tissues 47 27 63.8% 52.2% 37.0%
Tumor location
(topography):
– Axial 59 38 67.8% 41.8% 32.2% 0.614
– Peripheral 54 34 72.2% 50.4% 31.7%
Disease extent at
diagnosis:
– Localized 54 27 79.6% 61.7% 43.1% 0.003
– Metastatic 55 42 60.0% 29.0% 20.1%
†Kaplan–Meier and log-rank methods.
MTAP: Methylthioadenosine phosphorylase.
Table 4. Multivariate Cox regression model for independent prognostic factors.
Characteristic HR 95% CI p-value
Inferior Superior
MTAP:
– Loss of expression 1.818 1.029 3.215 0.039
– Positive expression 1 —- —-
Ethnicity:
– White 1 —- —- 0.001
– Non-white 3.401 1.643 7.037
Age:
– ≤20 years 1 —- —- 0.084
– 20 years 1.754 0.928 3.314
Disease extent at diagnosis:
– Localized 1 —- —- 0.002
– Metastatic 2.476 1.400 4.377
HR: Hazard ratio; MTAP: Methylthioadenosine phosphorylase.
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Figure 2. Kaplan–Meier overall survival curves according to methylthioadenosine phosphorylase expression
Table 5. Multivariate Cox regression model in metastatic and nonmetastatic patients.
Patients’ group MTAP HR 95% CI p-value
Inferior Superior
Metastatic Loss of expression 2.352 1.135 4.878 0.021
(n = 54) Positive expression 1 —- —-
Nonmetastatic Loss of expression 2.334 0.450 12.107 0.313
(n = 53) Positive expression 1 —- —-
HR: Hazard ratio; MTAP: Methylthioadenosine phosphorylase.
ESFT are known to be more common in white patients when compared with patients from other ethnic groups,
according to literature data [9,10,14,15]. Jawad et al. (2009) [14] in a retrospective analysis of 1631 cases from the
population-based SEER (Surveillance, Epidemiology and End Results) program of the National Cancer Institute
showed that Caucasians had a ninefold higher incidence of ESFT than African-Americans. In the present study,
83% of the patients (n = 93) were white, corroborating the data in the literature and presenting numbers that
were practically identical to those of the first multicentric study of the Brazilian Group for Treatment of ESFT, by
Brunetto et al. (2015) [10], which showed 82.9% of white patients in a total of 175 cases studied. Ethnicity was an
independent prognostic factor in our study (p= 0.003). Non-white patients had OS rates lower than those of white
patients. In fact, non-white patients had a 3.4-fold higher risk of death when compared with white patients (95%
CI: 1.64–7.03). Worch et al. (2010) [15], in a large retrospective study of 1715 patients from the SEER database,
showed that OS was significantly different according to the ethnicity/race of the patients, being lower in non-white
patients, in agreement with our results. These differences in clinical outcomes may reflect socioeconomic and
biological differences or a combination of both factors. It is known that the socioeconomic reality of the non-white
population, especially black and indigenous, is extremely unfavorable in Brazil. The low socioeconomic status could
future science group 10.2217/bmm-2017-0152
Research Article Abrahao-Machado, Antunes, Filippi et al.
Synthesis of
polyamine
De novo
synthesis of
purines
MTAP Adenine AMP ATP
MTA
MTR-1-P Methyonine
Figure 3. Methylthioadenosine phosphorylase metabolic pathway. In normal cells, MTAP cleaves MTA, a byproduct
of polyamine biosynthesis, into adenine and MTR-1-P. In MTAP-deficient cells, however, the MTA is not cleaved and
the salvage pathway for adenine and methionine is absent, with a stimulus for the de novo synthesis of purines.
MTA: Methylthioadenosine; MTAP: Methylthioadenosine phosphorylase; MTR-1-P: 5-methylthioribose-1-phosphate.
limit or delay the access of these patients to the diagnosis and treatment, thus influencing their prognoses. Biological
differences may include variations in tumor aggressiveness and host factors, such as genetic differences that would
influence tumor metabolism and response to treatment. However, broader and more focused studies are needed
to investigate these possible biological and genetic differences among ethnicities, as well as additional studies on
disparities in health care access to assess the role of these factors in explaining the differences in the outcomes.
The MTAP biomarker showed loss of expression in 27.9% of the cases (n = 31). To best of our knowledge,
these findings have never been reported in ESFT. Besides, this is the first study to show the association of loss of
MTAP expression with shorter OS in these patients.
MTAP is expressed in all normal tissues, but is often deleted in some tumors, mainly in co-deletion with the
CDKN2A gene. Therefore, it is attributed a tumor suppression function to the MTAP gene [4,16]. In normal cells,
the MTAP protein acts on the purine biosynthesis pathway, being important to the salvage process of adenine and
methionine by cleaving the substrate 5′-deoxy-5′-Methylthioadenosine (MTA) generated during the biosynthesis
of polyamines, and producing adenine and 5-methylthioribose-1-phosphate (MTR-1-P), which is later converted
to methionine. This pathway is the only known source of free adenine in the cells (Figure 3).
Inactivation of MTAP and the loss of its expression in tumor cells are associated with the de novo synthesis
of purines, which results in increased cell proliferation and, consequently, more aggressive tumor subtypes [4]. In
the study by Su et al. (2014), loss of MTAP expression in a series of non-small-cell lung carcinomas, assessed by
IHC, was independently associated with prognosis [3]. Also in line with our results, He et al. (2015) demonstrated
that MTAP deficiency was correlated with a more aggressive phenotype of nasopharyngeal carcinoma and with
shorter survival [17]. Recently, Nan et al. (2017) concluded that low MTAP expression was also associated with
poorer prognosis in ovarian cancer [18]. In the present study, the ESFT patients with loss of MTAP expression
had a 1.81-times greater risk of death when compared with patients with positive immunoexpression (95% CI:
1.02–3.21). When the patients were classified into metastatic and nonmetastatic groups, loss of MTAP expression
showed significant correlation with OS only in the metastatic group, in both univariate and multivariate analyses
(p = 0.021). In fact, in the metastatic group, patients with MTAP loss were 2.35-times more likely to die rather
than patients with MTAP positivity (95% CI: 1.13–4.87). These results suggest that MTAP is a prognostic factor,
particularly robust in advanced cases, probably due to the biological mechanisms of aggressiveness associated with
its deficiency. However, apart from OS, our results did not demonstrate association of MTAP with any other
clinical feature commonly related to tumor aggressiveness, such as tumor size and metastasis. We believe that the
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high number of patients with large tumors and metastases by the time of diagnosis in this series may have affected
the statistical results and masked any possible relation of this marker with these variables. Besides, we cannot rule
out the possibility of MTAP having an association with treatment response, which was not explored in this study.
Therefore, further studies are warranted for extending and validating the present important findings.
The finding that the MTAP enzyme is generally absent in some types of cancer has led to the proposition
of selective therapies, which utilizes gene deficiency to specifically target MTAP-negative tumor cells [19]. In this
context, the analysis of MTAP expression in ESFT may contribute to the development and employment of new
therapeutic strategies. The currently used protocols for chemotherapy in ESFT include five agents: vincristine,
doxorubicin, cyclophosphamide, ifosfamide and etoposide (VDC/IE). Therefore, in addition to the significance in
prognosis, MTAP could also have an important role as a target for molecular therapies to be developed. Also, MTAP
may have a potential as a predictor of responsiveness to some available drugs. Recent researches involving other
types of cancer, such as the study by De Oliveira et al. (2016) in breast cancer [4], have shown that tumor cells with
loss of MTAP, due to gene deletion or methylation of the MTAP promoter, are more sensitive to purine synthesis
inhibitor agents such as methotrexate, azathioprine and 5′-fluorouracil (5′-FU) [1,2]. Despite these drugs did not
appear to have a significant therapeutic activity against the ESFT in the past [20], and the relative success of current
strategies in cases of localized disease, the possibility of using a combination of both schemes in MTAP-negative
cases cannot be disregarded after prospective studies. Thus, a subset of patients with ESFT exhibiting loss of MTAP
could potentially benefit from treatment with specific chemotherapy, especially when disease is disseminated and is
not responding to conventional treatment.
Conclusion
With these evidences, it is demonstrated that the loss of MTAP expression may be useful as a predictor of
worse prognosis in patients with ESFT. MTAP along with other biomarkers and clinical factors associated with
the prognosis may aid in the elaboration of a future risk stratification for these tumors and even stimulate the
development of specific targeted drugs, especially for advanced disease.
Summary points
 Ewing sarcoma family of tumors (ESFT) are neoplasms of primitive neuroectodermal cells with an aggressive
biological behavior and poor outcomes.
 Survival rates for patients with metastatic or recurrent ESFT have not improved as much as rates for patients with
localized disease during the last decades.
 Loss of methylthioadenosine phosphorylase (MTAP) expression is observed in approximately 28% of ESFT.
 Loss of MTAP expression is an independent prognostic factor associated with shorter overall survival in patients
with ESFT.
 In MTAP-deficient cells, the salvage pathway for adenine and methionine is absent, causing a stimulus for the de
novo synthesis of purines which is associated with increased tumor aggressiveness.
 The use of MTAP as a prognostic biomarker in ESFT may aid in the risk stratification of patients and stimulate the
development of specific targeted drugs.
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